Literature DB >> 17394203

Barth syndrome associated with compound hemizygosity and heterozygosity of the TAZ and LDB3 genes.

Nicola Marziliano1, Savina Mannarino, Luisa Nespoli, Marta Diegoli, Michele Pasotti, Clara Malattia, Maurizia Grasso, Andrea Pilotto, Emanuele Porcu, Arturo Raisaro, Claudia Raineri, Roberto Dore, Pietro Paolo Maggio, Agnese Brega, Eloisa Arbustini.   

Abstract

Barth syndrome is an X-linked recessive disorder caused by the tafazzin (TAZ) gene mutations and includes dilated cardiomyopathy (DCM) with left ventricular non-compaction, neutropenia, skeletal myopathy, abnormal mitochondria and 3-methylglutaconic aciduria. Dilated cardiomyopathy with left ventricular non-compaction transmitted as an autosomal dominant condition has also been associated with LIM domain-binding 3 (LDB3) gene defects. We describe a family in which the 12-year-old proband had left ventricular non-compaction and DCM. His mother had five miscarriages, two other sons who died in infancy, and a healthy son and daughter. The proband showed left ventricular non-compaction-DCM, skeletal myopathy, recurrent oral aphthous ulcers and cyclic neutropenia. The DCM progressively improved with age; medical therapy was discontinued at 5 years of age. At present, left ventricular function is normal and arrhythmias are absent. Magnetic resonance imaging documented left ventricular non-compaction. However, oral aphthous ulcers and cyclic neutropenia have recurred. In the proband we identified two novel mutations, one of maternal origin in the TAZ gene (p.[Glu202ValfsX15]) and one of paternal origin in the LDB3 gene (p.[Thr350Ile]). The mother, brother and father are healthy; although the latter two show prominent left ventricle trabeculation without dysfunction. Expression studies of TAZ and LDB3 genes were conducted in family members and controls. In the proband, brother and father, LDB3 expression was similar to control cases. TAZ and LDB3 expression progressively declined with age in control both blood and myocardial samples. However, an endomyocardial biopsy performed in the proband at 6 months of age, showed significantly lower TAZ and LDB3 expression than in age-matched myocardial controls. We believe that the clinical, genetic and expression data support the hypothesis that tafazzins are essential during fetal and early post-natal life.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17394203     DOI: 10.1002/ajmg.a.31653

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  19 in total

Review 1.  Acute metabolic decompensation and sudden death in Barth syndrome: report of a family and a literature review.

Authors:  Ting-Yu Yen; Wuh-Liang Hwu; Yin-Hsiu Chien; Mei-Hwan Wu; Ming-Tai Lin; Lon-Yen Tsao; Wu-Shiun Hsieh; Ni-Chung Lee
Journal:  Eur J Pediatr       Date:  2007-09-11       Impact factor: 3.183

2.  Familial dilated cardiomyopathy. Clinical and genetic characteristics.

Authors:  A Serio; N Narula; T Kodama; V Favalli; E Arbustini
Journal:  Herz       Date:  2012-12       Impact factor: 1.443

3.  Understanding, treating and avoiding hematological disease: better medicine through mathematics?

Authors:  David C Dale; Michael C Mackey
Journal:  Bull Math Biol       Date:  2014-09-12       Impact factor: 1.758

4.  Cardiolipin-induced activation of pyruvate dehydrogenase links mitochondrial lipid biosynthesis to TCA cycle function.

Authors:  Yiran Li; Wenjia Lou; Vaishnavi Raja; Simone Denis; Wenxi Yu; Michael W Schmidtke; Christian A Reynolds; Michael Schlame; Riekelt H Houtkooper; Miriam L Greenberg
Journal:  J Biol Chem       Date:  2019-06-11       Impact factor: 5.157

Review 5.  TAZ encodes tafazzin, a transacylase essential for cardiolipin formation and central to the etiology of Barth syndrome.

Authors:  Anders O Garlid; Calvin T Schaffer; Jaewoo Kim; Hirsh Bhatt; Vladimir Guevara-Gonzalez; Peipei Ping
Journal:  Gene       Date:  2019-10-21       Impact factor: 3.688

6.  Selective deletion of long but not short Cypher isoforms leads to late-onset dilated cardiomyopathy.

Authors:  Hongqiang Cheng; Ming Zheng; Angela K Peter; Kensuke Kimura; Xiaodong Li; Kunfu Ouyang; Tao Shen; Li Cui; Derk Frank; Nancy D Dalton; Yusu Gu; Norbert Frey; Kirk L Peterson; Sylvia M Evans; Kirk U Knowlton; Farah Sheikh; Ju Chen
Journal:  Hum Mol Genet       Date:  2011-02-08       Impact factor: 6.150

7.  Intrafamilial variability for novel TAZ gene mutation: Barth syndrome with dilated cardiomyopathy and heart failure in an infant and left ventricular noncompaction in his great-uncle.

Authors:  Diti Ronvelia; Jaclyn Greenwood; Julia Platt; Simin Hakim; Michael V Zaragoza
Journal:  Mol Genet Metab       Date:  2012-09-18       Impact factor: 4.797

8.  Neutropenia in Barth syndrome: characteristics, risks, and management.

Authors:  Colin G Steward; Sarah J Groves; Carolyn T Taylor; Melissa K Maisenbacher; Birgitta Versluys; Ruth A Newbury-Ecob; Hulya Ozsahin; Michaela K Damin; Valerie M Bowen; Katherine R McCurdy; Michael C Mackey; Audrey A Bolyard; David C Dale
Journal:  Curr Opin Hematol       Date:  2019-01       Impact factor: 3.284

Review 9.  Cardiogenetics, neurogenetics, and pathogenetics of left ventricular hypertrabeculation/noncompaction.

Authors:  Josef Finsterer
Journal:  Pediatr Cardiol       Date:  2009-01-29       Impact factor: 1.655

10.  A Novel Exonic Splicing Mutation in the TAZ (G4.5) Gene in a Case with Atypical Barth Syndrome.

Authors:  Yuxin Fan; Jon Steller; Iris L Gonzalez; Wim Kulik; Michelle Fox; Richard Chang; Brandy A Westerfield; Anjan S Batra; Raymond Yu Jeang Wang; Natalie M Gallant; Liana S Pena; Hu Wang; Taosheng Huang; Sunita Bhuta; Daniel J Penny; Edward R McCabe; Virginia E Kimonis
Journal:  JIMD Rep       Date:  2013-04-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.